Download Files:
Irsenontrine
$220 – $5,400
Products Details
Product Description
– Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine can be used for the research of neurological diseases[1][2][3].
Web ID
– HY-132821
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C22H22N4O3
References
– [1]Miyamoto, et al. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine. WO2018221550 A1|[2]Hershey LA, et al. Pharmacological Management of Dementia with Lewy Bodies. Drugs Aging. 2019;36(4):309-319.|[3]Eisai to present latest research on Alzheimer’s disease / dementia pipeline at the 14th international conference on Alzheimer’s & Parkinson’s diseases
CAS Number
– 1429509-82-9
Molecular Weight
– 390.44
Compound Purity
– 99.91
SMILES
– O=C1C2=C(N([C@@]3([H])CCOC3)N=C2)C4=CC=C(C5=C(C)C=NC(OC)=C5C)C=C4N1
Clinical Information
– Phase 2
Research Area
– Neurological Disease
Solubility
– DMSO : 12.5 mg/mL (warming;heat to 60°C)
Target
– Phosphodiesterase (PDE)
Isoform
– PDE9
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
